new review article on treatment of her2+ breast cancer by Dr Pegram

[Lani]

Dr Pegram worked hand-in-hand with Dr Slamon for decades before moving to Miami and now Stanford.

He hosts an large number of panel discussions and poster discussion seions on her2+ bc at SABCS, ASCO, and other bc specific conferences

Unfortunately it does not appear to be open access.






Hematol Oncol Clin North Am. 2013 Aug;27(4):751-765. doi: 10.1016/j.hoc.2013.05.007.
Treating the HER2 Pathway in Early and Advanced Breast Cancer.
Pegram MD.
Source
Medical Oncology, Stanford Cancer Institute, Stanford University School of Medicine, G2021B Lorry I. Lokey Building, 265 Campus Drive West, Stanford, CA 94305-5456, USA; Stanford Breast Oncology Program, Stanford Cancer Institute, Stanford University School of Medicine, G2021B Lorry I. Lokey Building, 265 Campus Drive West, Stanford, CA 94305-5456, USA; Molecular Therapeutics Program, Stanford Cancer Institute, Stanford University School of Medicine, G2021B Lorry I. Lokey Building, 265 Campus Drive West, Stanford, CA 94305-5456, USA. Electronic address: mpegram@stanford.edu.
Abstract
ERBB2 gene amplification occurs in ∼20% of human breast cancers (BC) and is associated with an adverse clinical prognosis, indicating that it may be playing a critical role in disease pathogenesis. Therapeutic strategies targeting pathologic ERBB2 overexpression have revolutionized the diagnosis and treatment of BC. Indeed, humanized anti-ERBB2 antibodies, small molecule ERBB2 kinase inhibitors and ERBB2-targeting antibody-drug conjugates have proven safety and efficacy based upon evidence from randomized phase III clinical trials. Recent progress in targeting ERBB2 alteration will be reviewed, with focus on data that has informed changes in clinical practice for the treatment of BC.
Copyright © 2013 Elsevier Inc. All rights reserved.
KEYWORDS:
Antibody-drug conjugate, HER2 pathway, Human breast cancers

PMID: 23915743